Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.
This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.
References
